Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Abeona Therapeutics (ABEO) over the last 14 years, with Q3 2025 value amounting to -$64.6 million.

  • Abeona Therapeutics' Cash from Investing Activities fell 94794.88% to -$64.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.4 million, marking a year-over-year increase of 34545.47%. This contributed to the annual value of -$39.2 million for FY2024, which is 1896538.46% down from last year.
  • Abeona Therapeutics' Cash from Investing Activities amounted to -$64.6 million in Q3 2025, which was down 94794.88% from $155.9 million recorded in Q2 2025.
  • Abeona Therapeutics' 5-year Cash from Investing Activities high stood at $155.9 million for Q2 2025, and its period low was -$64.6 million during Q3 2025.
  • In the last 5 years, Abeona Therapeutics' Cash from Investing Activities had a median value of $2.2 million in 2023 and averaged $5.2 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first skyrocketed by 48383.51% in 2021, then crashed by 123662.83% in 2023.
  • Abeona Therapeutics' Cash from Investing Activities (Quarter) stood at $8.0 million in 2021, then crashed by 416.16% to -$25.3 million in 2022, then skyrocketed by 145.59% to $11.5 million in 2023, then soared by 63.73% to $18.9 million in 2024, then plummeted by 442.38% to -$64.6 million in 2025.
  • Its last three reported values are -$64.6 million in Q3 2025, $155.9 million for Q2 2025, and $4.2 million during Q1 2025.